{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05734521",
            "orgStudyIdInfo": {
                "id": "OBS17641"
            },
            "organization": {
                "fullName": "Sanofi",
                "class": "INDUSTRY"
            },
            "briefTitle": "Avalglucosidase Alfa Pregnancy Study",
            "officialTitle": "A Descriptive Safety Study Based on Data Collected From Women and Their Offspring Exposed to Nexviazyme/Nexviadyme (Avalglucosidase Alfa-ngpt/Avalglucosidase Alfa) During Pregnancy and/or Lactation in the Postmarketing Setting",
            "therapeuticArea": [
                "Women's Health",
                "Other"
            ],
            "study": "avalglucosidase-alfa-pregnancy-study"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-10-26",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2032-10",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2032-10",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-02-03",
            "studyFirstSubmitQcDate": "2023-02-15",
            "studyFirstPostDateStruct": {
                "date": "2023-02-21",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-12",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-15",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Sanofi",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a worldwide, descriptive safety study collecting data on women and their offspring exposed to avalglucosidase alfa during pregnancy and/or lactation, to assess the risks of avalglucsodiase alfa on pregnancy and maternal complications and adverse effects in the developing fetus, neonate, and infant.\n\n* Outcomes in exposed infants, including growth and development, will be assessed through at least the first year of life.\n* Data will be collected for approximately 10 years.",
            "detailedDescription": "Study Design Time Perspective: Retrospective and Prospective"
        },
        "conditionsModule": {
            "conditions": [
                "Pompe Disease",
                "Pregnancy"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "OTHER"
            },
            "enrollmentInfo": {
                "count": 100,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Pregnant women exposed to avalglucosidase alfa",
                    "description": "Pregnant women with a confirmed diagnosis of Pompe disease and avalglucosidase alfa exposure during the pregnancy and/or lactation",
                    "interventionNames": [
                        "Biological: avalglucosidase alfa-NGPT (GZ402666) IV"
                    ]
                },
                {
                    "label": "Infants born to mother/father exposed to avalglucosidase alfa",
                    "description": "Infants born to mother/father with a confirmed diagnosis of Pompe disease and exposed to avalglucosidase alfa",
                    "interventionNames": [
                        "Biological: avalglucosidase alfa-NGPT (GZ402666)"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "avalglucosidase alfa-NGPT (GZ402666) IV",
                    "description": "intravenous infusion",
                    "armGroupLabels": [
                        "Pregnant women exposed to avalglucosidase alfa"
                    ],
                    "otherNames": [
                        "NEXVIAZYME"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "avalglucosidase alfa-NGPT (GZ402666)",
                    "description": "exposed via pregnancy and lactation",
                    "armGroupLabels": [
                        "Infants born to mother/father exposed to avalglucosidase alfa"
                    ],
                    "otherNames": [
                        "NEXVIAZYME"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Maternal complications",
                    "description": "Prevalence of pregnancy/labor/delivery/postpartum maternal complications",
                    "timeFrame": "through study completion, an average of 10 years"
                },
                {
                    "measure": "Pregnancy outcome",
                    "description": "Prevalence of live births, spontaneous abortions (\\<20 weeks of gestation), elective terminations, ectopic pregnancies, early fetal deaths (20 to 27 weeks of gestation), late fetal deaths (\u226528 weeks of gestation), stillbirths and maternal deaths",
                    "timeFrame": "through study completion, an average of 10 years"
                },
                {
                    "measure": "Infant outcome",
                    "description": "Number of occurrences of major congenital anomalies, neonatal deaths, development delays (growth, motor, neurologic, behavioral) through first year of life.\n\nMajor congenital anomalies defined using the US Centers for Disease Control and Prevention (CDC) and growth and development assessments using CDC's Developmental Milestones 2021.",
                    "timeFrame": "through study completion, an average of 10 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Women and their offspring exposed to avalglucosidase alfa during pregnancy and/or lactation for whom an Individual Case Safety Report (ICSR) has been submitted to the Sanofi Global Pharmacovigilance (PV) department, and/or,\n* Women exposed to avalglucosidase alfa during pregnancy and/or lactation who have provided informed consent to enroll in the Pompe Pregnancy Sub-registry.\n\nExclusion Criteria:\n\nThere are no exclusion criteria in this study.\n\nThe above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.",
            "healthyVolunteers": false,
            "sex": "FEMALE",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Women and their offspring exposed to avalglucosidase alfa during pregnancy and/or lactation",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Trial Transparency email recommended (Toll free for US & Canada)",
                    "role": "CONTACT",
                    "phone": "800-633-1610",
                    "phoneExt": "option 6",
                    "email": "Contact-US@sanofi.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Clinical Sciences & Operations",
                    "affiliation": "Sanofi",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Investigational site worldwide",
                    "status": "RECRUITING",
                    "city": "Bridgewater",
                    "state": "New Jersey",
                    "zip": "08807",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.60079,
                        "lon": -74.64815
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000006009",
                    "term": "Glycogen Storage Disease Type II"
                }
            ],
            "ancestors": [
                {
                    "id": "D000020140",
                    "term": "Lysosomal Storage Diseases, Nervous System"
                },
                {
                    "id": "D000020739",
                    "term": "Brain Diseases, Metabolic, Inborn"
                },
                {
                    "id": "D000001928",
                    "term": "Brain Diseases, Metabolic"
                },
                {
                    "id": "D000001927",
                    "term": "Brain Diseases"
                },
                {
                    "id": "D000002493",
                    "term": "Central Nervous System Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000008661",
                    "term": "Metabolism, Inborn Errors"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                },
                {
                    "id": "D000006008",
                    "term": "Glycogen Storage Disease"
                },
                {
                    "id": "D000002239",
                    "term": "Carbohydrate Metabolism, Inborn Errors"
                },
                {
                    "id": "D000016464",
                    "term": "Lysosomal Storage Diseases"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M9115",
                    "name": "Glycogen Storage Disease Type II",
                    "asFound": "Pompe Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9114",
                    "name": "Glycogen Storage Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "M18871",
                    "name": "Lysosomal Storage Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5204",
                    "name": "Brain Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5205",
                    "name": "Brain Diseases, Metabolic",
                    "relevance": "LOW"
                },
                {
                    "id": "M22498",
                    "name": "Brain Diseases, Metabolic, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "M5742",
                    "name": "Central Nervous System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M11641",
                    "name": "Metabolism, Inborn Errors",
                    "relevance": "LOW"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "M5498",
                    "name": "Carbohydrate Metabolism, Inborn Errors",
                    "relevance": "LOW"
                },
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T2562",
                    "name": "Glycogen Storage Disease Type 2",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}